- PCSA Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Processa Pharmaceuticals (PCSA) CORRESPCorrespondence with SEC
Filed: 6 Jul 21, 12:00am
Processa Pharmaceuticals, Inc.
7380 Coca Cola Drive, Suite 106
Hanover, Maryland 21076
July 6, 2021
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Ms. Christine Westbrook
Re: | Processa Pharmaceuticals, Inc. | |
Registration Statement on Form S-3 (Registration No. 333-257558) |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Processa Pharmaceuticals, Inc. (the “Registrant”), hereby requests acceleration of effectiveness of its above-referenced Registration Statement to 12:00 P.M., Eastern time, on July 9, 2021, or as soon as practicable thereafter. For purposes of Rules 460 and 461, there is no underwriter. The Registrant respectfully requests that you notify Mr. John Wolfel of Foley & Lardner LLP of such effectiveness by a telephone call to (904) 359-8778.
Very truly yours, | ||
Processa Pharmaceuticals, Inc. | ||
By: | /s/ James Stanker | |
James Stanker | ||
Chief Financial Officer |